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Abstract
Purpose: To investigate radiation oncologists’ opinions on important considerations to offering re-irradiation (re-RT)
as a treatment option for recurrent glioma.
Materials and methods: A survey was conducted with 13 radiation oncologists involved in the care of central
nervous system tumor patients. The survey was comprised of 49 questions divided into 2 domains: a demographic
section (10 questions) and a case section (5 re-RT cases with 5 to 6 questions representing one or several re-RT
treatment dilemmas as may be encountered in the clinic). Respondents were asked to rate the relevance of various
factors to offering re-RT, respond to the cases with a decision to offer re-RT vs. not, volume to be treated, margins
to be employed, dose/fractionation suggested and any additional comments with respect to rationale in each
scenario.
Results: Sixty nine percent of responders have been practicing for greater than 10 years and 61% have re-RT 20 to
100 patients to date, with 54% seeing 2–5 re-RT cases per month and retreating 1–2 patients per month. Recurrent
tumor volume, time since previous radiation therapy, previously administered dose to organs at risk and patient
performance status were rated by the majority of responders (85%, 92%, 77%, and 69% respectively) as extremely
relevant or very relevant to offering re-RT as an option.
Conclusion: The experts’ practice of re-RT is still heterogeneous, reflecting the paucity of high-quality prospective
data available for decision-making. Nevertheless, practicing radiation oncologists can support own decisions by
referring to the cases found suitable for re-RT in this survey.
Introduction
Seventy-eight thousand brain tumors are diagnosed in
the United States per year with gliomas representing
approximately one third [1]. Virtually all gliomas eventu-
ally recur following treatment and in their natural
history carry devastating neurological and psychological
implications for those affected. Patients with a diagnosis
of glioma may undergo multiple resections, radiation
therapy and multiple lines of systemic treatment with
diminishing treatment options as the disease progresses.
Re-irradiation (re-RT) as a possible treatment option
often enters the discussion and multiple retrospective
studies have shown re-RT to be feasible and to improve
outcome in selected patients [2–13]. The benefits of
re-RT include possible palliation by way of decreased
steroid use, improvement in neurological symptoms, and
in some patients an improvement in progression free
survival and possibly overall survival. The timing of
re-RT offering the best opportunity for benefit is un-
clear. Patient selection for re-RT varies according to the
study, institution and available techniques and hence the
type of patient who may benefit from its administration
remains unclear. Prognostic scores using retrospective
data have attempted to identify patient strata that may
benefit from re-RT based on patient and histological
factors [14–17]. Significant heterogeneity in manage-
ment has proven difficult with some studies reporting
validation of existing scoring systems and others not.
The radiation dose to be administered and its fraction-
ation as well as the co-administration of chemotherapy
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suffer from lack of consensus and are as yet unclear.
Re-RT is the subject of several ongoing trials, the results
thereof, although highly relevant and anticipated, none-
theless are likely to leave us with unanswered questions.
Many patients with recurrent glioma who may be con-
sidered for re-RT in the clinic would not necessarily
have been eligible for the ongoing trials but according to
existing data may nonetheless derive benefit from re-RT
and may receive re-RT when no other options are
available.
The intent of this publication was to obtain the opin-
ion of radiation oncologists who 1) share an interest in
the re-RT of patients with recurrent glioma defined as
having published at least one paper on the subject and
or having an ongoing practice or open protocol pertain-
ing to re-RT or 2) have treated a significant number of
cases. A simple but robust survey was employed as the
springboard for expert discussion in an effort to gain a
better understanding of patient selection and the phil-
osophy underlying the re-RT dose and fractionation
being offered.
Materials and methods
Survey development
The survey began with the referral and treatment of
patients with recurrent glioma seen in clinic and pre-
sented at NCI NIH CNS tumor boards where re-RT as
option came up and a radiation oncology opinion was
requested. We noted that cases shared features that
made the decision to offer re-RT or the feasibility
thereof from a planning perspective difficult. Knowing
that the level of expertise of the responder and the
clinical load of re-RT cases they are faced with, was as
relevant as the cases themselves, the survey is divided
into 2 domains: a demographic section containing 10
questions aiming to assess the load of re-RT cases the
responder has treated/is treating and their institution of
practice and a second section containing 5 re-RT cases
with 5 to 6 questions associated with each case aimed at
eliciting a response with respect to one or several re-RT
treatment dilemmas as may be encountered in the clinic.
The survey consisted of 49 total questions over 7 pages
with 6 associated images (Additional file 1).
Question generation
The Survey Monkey survey (Additional file 1) was devel-
oped in several stages starting with review of the litera-
ture in conjunction with commonly arising re-RT
questions in the clinic. This was followed by multiple
iterations of the questionnaire itself which was written
by the primary author (AK), and reviewed by two
experts (KC and DS) for relevance, accuracy and usabil-
ity of each item. Subsequently the survey was tested by
KC, DS and LR for functionality. With respect to factors
of relevance to offering re-RT as a treatment option clin-
ically identified and literature described factors were
included. However, we also gave the responder the
opportunity to add other factors they felt were relevant
in addition to the ones provided.
Survey distribution
The survey was distributed with the intent of obtaining
relevant responses from radiation oncologists with a
range of experience who share an interest in re-RT of
patients with recurrent glioma as evidenced by previous
publications on the subject and/or upon recommenda-
tion of a peer who shared that interest. In order to
capture the wide range of approaches to this challenging
clinical scenario, we did elect to also include responders
who are just starting out in re-irradiation and “up and
coming” investigators with an interest in the field. The
ultimate goal is to have a wider range of responders post
publication when the survey is open to readers. The 13
potential responders were contacted by email and
informed of the research proposed in association with
the survey and offered contribution to the publication
and all responded to the questionnaire.
The responders were asked to provide both binary
answers regarding the intention to re-irradiate as well as
quantitative answers with respect to margins and doses
employed and were given the option to explain their ration-
ale in an associated comment section. The questionnaire
was administered between August and November 2016.
Results
Survey results
Thirteen radiation oncology experts, 8 from the United
States and 5 from Europe responded to the survey and
are included as co-authors on this manuscript. All of the
responses have been anonymized.
Expertise of responders
Sixty nine percent (9/13) of the contributing radiation
oncologists have been practicing for greater than 10 years
(Fig 1). The majority, 62% (8/13) have re-irradiated 20 to
100 patients to date and 54% (7/13) see 2 to 5 potential
re-RT cases per month. Fifty four percent (7/13) retreat
1–2 patients per month and 38% (5/13) retreat 2 to 5
patients. For 85% (11/13) of responders “some of the
patients” receive re-RT on a clinical research protocol.
Factors underlying the decision to offer re-RT
Responders were offered 11 clinical factors to rate in
terms of relevance to the decision to offer re-RT
(Table 1). Time since previous radiation therapy, tumor
volume, previously administered dose to organs at risk
and patient performance status were felt by the majority
of responders (92%, 85%, 77%, and 69% respectively) to
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be extremely relevant or very relevant to offering re-RT
as an option (Table 1). This was followed by patient age,
number of lines of previous treatment, original histology,
and previous use of bevacizumab (BEV)/BEV failure
which were rated as very relevant or somewhat relevant
in 93%, 84%, 77%, 77% respectively. No responders rated
patient age, number of lines of previous treatment, DWI
perfusion characteristics and FDG-PET avidity as
extremely relevant but 1 responder (a different one in
each case) did rate original histology, tissue documenta-
tion of recurrence, and previous use of BEV/BEV failure
as extremely relevant, conversely. Fifty four percent of
responders rated available tissue documentation of
tumor progression and DWI characteristics as somewhat
relevant, 46% previous use of BEV/BEV failure as some-
what relevant while 46% rated PET avidity of the lesion
as not at all relevant. Responders were given the oppor-
tunity to comment on additional factors they would
consider relevant when considering offering re-RT as
free text in the survey. Responses included rate of tumor
growth, molecular markers (IDH mutation status,
MGMT methylation status), availability of high precision
techniques, patient preference, favorable location vs.
overlapping OAR, long natural history, surgical
Fig. 1 Level of expertise and experience of survey responders. a Number of years practicing radiation oncology. b Number of patients
re-irradiated to date. c Number of potential glioma re-irradiation cases seen per month. d Number of patients re-irradiated per month
Table 1 Factors considered in offering re-irradiation as a treatment option
Responder number/(%)
Factor Extremely relevant Very relevant Somewhat relevant Not at all relevant
Tumor volume 5 (38) 7 (54) 1 (8) 0 (0)
Time since previous radiation therapy 6 (46) 6 (46) 1 (8) 0 (0)
Dose previously administered to organs at risk in the field 6 (46) 4 (31) 3 (23) 0 (0)
Patient performance status 5 (38) 4 (31) 4 (31) 0 (0)
Patient age 0 (0) 8 (62) 4 (31) 1 (8)
Original histology 1 (8) 4 (31) 6 (46) 2 (15)
Number of lines of previous treatment 0 (0) 5 (38) 6 (46) 2 (15)
Previous use of Bevacizumab or Bevacizumab failure 1 (8) 4 (31) 6 (46) 2 (15)
Available tissue documentation of tumor progression 1 (8) 3 (23) 7 (54) 2 (15)
Perfusion characteristics on diffusion weighted imaging (DWI) 0 (0) 6 (46) 7 (54) 0 (0)
PET avidity of the lesion 0 (0) 4 (31) 3 (23) 6 (46)
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resectability and unifocal vs. multifocal disease and ability
to travel for treatment. The presence of symptoms was
not noted as an additional factor by any of the responders.
In assessing which measures are being routinely per-
formed as part of decision making when re-RT is consid-
ered 100% of the responders employed multidisciplinary
discussions, 100% obtained previous RT summaries
including DVH and field arrangements, nearly 92% also
obtained the plan in DICOM format to create a plan sum
and 100% calculated cumulative dose to OAR taking into
account the previous treatment plans.
Re-irradiation cases
Case 1
This case involved a small in-field recurrence with a reason-
ably favorable location in a younger patient who was 2 years
out from chemoirradiation and had not been rechallenged
with additional systemic agents (Fig. 2a).
All the responders considered offering re-RT to this
patient (Fig. 3), though 1 responder did suggest seed
implantation may be discussed as a possible next step.
77% of responders would treat the T1 gadolinium
enhancing volume, with the remainder choosing to treat
both the T1 gadolinium and the T2 FLAIR volume. Sixty
two percent would employ a less than 0.5 cm cumulative
margin and 31% would employ a margin ranging of 0.5
to 1 cm. Three responders would treat using stereotactic
radiosurgery (SRS) techniques employing doses ranging
from 18 to 25 Gy. The remainder of responders offered
hypofractionated RT (62%), (30 to 43.2Gy in 5 to 18
fractions) or conventional fractionation (15%) (45–54 Gy
in 25 to 30 fractions) (Fig. 3). Case 1 comments in-
cluded: “dosing will depend on how much normal struc-
tures received in prior treatment; typically use 5
fractions or 10 if concerned with cumulative RT dose to
normal structures” and “PRDR (pulsed reduced dose
rate) is a technique that reduces the apparent rate at
Fig. 2 Imaging for the survey cases. a Case 1: a small in-field recurrence with a reasonably favorable location in a young patient who was 2 years out
from chemoirradiation and had not been rechallenged with additional systemic agents. b Case 2: a small edge of field, biopsy proven recurrence in a
reasonably favorable location in a younger patient almost 2 years out from treatment who had also failed Bevacizumab treatment. c Case 3: a larger in
field recurrence, in an unfavorable location a considerable time out from treatment (11 years) who was heavily chemo-retreated, and had also failed
Bevacizumab treatment. d Case 4: a very large in field recurrence in an older patient with a very good performance status who had completed
chemoirradiation less than a year prior. e Case 5: a younger patient with an original histologic diagnosis of anaplastic astrocytoma who had done very
well for 5 years until out of field progression was noted for which he was asymptomatic
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Fig. 3 Re-irradiation case characteristics according to factors of relevance to offering re-RT as a treatment option and survey responses
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which the treatment is delivered to 6.67 cGy/min” as
well as “Chemotherapy with Bevacizumab/CCNU” and
“I would include PET-avid areas extending beyond the
T1Gd MRI volume”. One responder summarized “Small
focal recurrence at time of recurrence at almost 2 years
post original treatment is not unreasonable to treat with
SRS. Not growing quickly, though we do not have info
on if FLAIR abnormality had progressed. if it has as well,
I'd be more apt to treat FLAIR.”
Case 2
In contrast to case 1 this young patient had a biopsy
proven recurrent glioblastoma outside of the 80%
isodose line and also progressed on BEV (Fig. 2b).
In contrast to case 1, only 77% of responders considered
offering re-RT to this patient, though 2 responder sug-
gested resection as a possible next step. In comparison
with case 1 the cumulative margin chosen in case 2 was
more evenly divided among the options with 33%, 33%,
33% opting for less than 0.5 cm, 0.5 to 1 cm, 1 to 2 cm
respectively, whilst in case 1 most responders had favored
a smaller margin. 67% of responders would treat the T1
gadolinium enhancing volume, with the remainder choos-
ing to treat both the T1 gadolinium plus the old resection
cavity. 58%, 33%, 8% of responders offered hypofractio-
nated re-RT (30 to 47.5 Gy in 5 to 19 fractions), conven-
tionally fractionated re-RT (45 to 59.4 Gy) and SRS
(18 Gy) respectively. This distribution was in contrast to
case 1, where more responders chose to offer SRS or more
extreme hypofractionation. As compared to case 1, in case
2, 42% responders decreased the dose per fraction they
would employ while the remainder kept the same dose
and fractionation in both cases (Fig. 3). Case 2 comments
included: “discussion with the patient regarding stereotac-
tic radiotherapy with single dose (18 Gy) or 6 * 5 Gy”,
“SRS if no significant T2 signal, if there is a large area of
T2 signal around the enhancement I would treat like the
prior case”. With respect to BEV: “BEV causes the en-
hancement to underestimate the extent of the tumor.
Moreover, this is an out of field failure. As such, I would
treat to near full dose and continue the BEV” and another
responder: “Treating only T1 increasing risk of marginal
failure for patients progressing on BEV”. A responder
summarized: “Large volume re-irradiation is justified
given the long natural history.”
Case 3
In contrast to both case 1 and 2, this case involved a
patient with glioblastoma who recurred 11 years follow-
ing initial treatment, was heavily chemo-retreated and
for whom all organs at risk in the field had previously
received maximal dose (Fig. 2c).
Compared to case 1 or 2, only 54% of responders con-
sidered offering re-RT to this patient. Responders who
chose to not offer re-RT did not do so as they felt that the
patient would benefit more from a clinical trial (23%) or
that the case was a palliative one with no role for re-RT
(15%). Similarly, to case 1 and 2, 64% of responders would
treat the T1 gadolinium enhancing volume, with the
remainder choosing to treat both the T1 gadolinium and
FLAIR volume. The cumulative margin chosen was 45%,
36%, 18%, for less than 0.5 cm, 0.5 to 1 cm, 1 to 2 cm re-
spectively, more similar to case 1 where more responders
favored a smaller margin but also reflecting the split in
margin employed observed in case 2. In contrast to both
case 1 and 2, only 33% of responders offered hypofractio-
nated re-RT (30 to 35 Gy in 10 fractions), while 58% of-
fered conventionally fractionated re-RT (36 to 54 Gy in 18
to 30 fractions) respectively. None of the responders
offered SRS. Unlike either case 1 or 2, 2 responders also
commented on continuing BEV and 2 others on the use of
concurrent chemotherapy (CCNU or Temozolomide and
BEV) (Fig. 3). Comments from the responders included:
“After Avastin GTV/CTV/PTV not clear in MRI, MET-
PET or FET-PET mandatory for RT decision”, “Consider
concurrent CCNU or Temodar and BEV, TTF”. With
respect to the OAR: “very high doses to the brainstem
may be expected; should consider a rather low dose due
to the size of the lesion” and “too big to hypofractionate.
The FLAIR is clearly also failing so I would want to in-
clude. Use IMRT to constrain brainstem and optics. would
want to continue the BEV on this case as well if possible.”
Case 4
Similar to case 3 this case involved a large recurrence
volume with OAR having previously been treated to
maximal dose however two features were in contrast to
all other cases in this series in that this case involved an
older patient (74 year old) who was out less than a year
from previous treatment (Fig. 2d).
In contrast to all other cases, only 15% of responders
considered offering re-RT to this patient, while the
remainder 11 did not. Responders who chose to not
offer re-RT did not do so as they felt that the recurrent
tumor volume was too large for re-RT to be meaningful
(31%) while the remainder felt that the patient would
benefit more from a systemic option (54%). The re-
sponders were asked to provide a volume, margin and
dose they would employ if they were to offer re-RT in
this case even if they did not recommend it. Only 54%
of responders did so. 71% of these would treat the gado-
linium enhancing volume only, whereas 29% would treat
both gadolinium enhancing volume and T2 FLAIR vol-
ume. The cumulative margin chosen was 57%, 29%, 14%,
for less than 0.5 cm, 0.5 to 1 cm, 1 to 2 cm respectively.
This bore the most similarity to the margin distribution
in case 3. 3 and 4 responders offered hypofractionated
re-RT (30 to 35 Gy in 10 fractions) and conventionally
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fractionated re-RT (36 to 54 Gy in 18 to 30 fractions)
respectively, also similar to dose and fractionations
offered in case 3. None of the responders offered SRS
(Fig. 3). One responder included: “Wouldn't use re-
irradiation at first failure this early for such a large
recurrence. Patient may actually benefit from BEV symp-
tomatically. clinical trial would be first option in my
opinion.” Another responder stated “too large volume
for a meaningful reirradiation” while another stated“-
chemotherapy with BEV and CCNU proposed”.
Case 5
In contrast to all the other cases, this case involved a
patient with a recurrent anaplastic astrocytoma. It does
share similarities otherwise to both case 1 and 2 as the
patient is young and the recurrence is some distance
away from the original resection (Fig. 2e).
Similarly, to Case 3, 69% of responders considered offer-
ing re-RT to this patient, while the remainder did not,
although interestingly none of the responders who did so in
case 3 overlap with case 5. Responders who chose to not
offer re-RT did not do so preferring to recommend clinical
trial (15%) or resection (15%). 67% of responders would
treat the gadolinium enhancing volume alone, 8% would
treat the gadolinium enhancing volume and the original
resection cavity, 25% would treat the gadolinium enhancing
volume, the original resection cavity and the T2 FLAIR vol-
ume. Similarly, to case 2, 31% responders would also re-RT
the original resection cavity although only 15% of them
overlapped with the two who did so in case 2. The cumula-
tive margin chosen was 33%, 58%, 8%, for less than 0.5 cm,
0.5 to 1 cm, 1 to 2 cm respectively. 75% and 25% of
responders offered hypofractionated re-RT (30 to 47.5 Gy
in 10 to 19 fractions) and conventionally fractionated re-RT
(36 to 54 Gy in 18 to 27 fractions) respectively. None of the
responders offered SRS (Fig. 3). Five Comments from 5 dif-
ferent responders emerged: “five years is a long time, I
would be aggressive”, “I would always recommend concur-
rent BEV with re-irradiation; that goes for all the cases I
mentioned before where I would re-treat.”, “T2 signal goes
around the chiasm. Feel better not treating the T2 if
additional systemic treatment is added” and “Would prefer
sampling of new and old site. If prior site consistent with
treatment changes only, then treat new foci only”. With
respect to OAR one responder summarized as follows:
“Limited volume out of field recurrence. Optic tolerance
will play a role in re-irradiation planning. Because of large
volume previously irradiated, I would want to just treat the
recurrent region and probably shouldn't go to full dose
given that the optics probably previously maxed out.”
Discussion
Re-irradiation is being offered for patients with recurrent
glioma at both academic centers and in the community,
on clinical protocols or outside of existing protocols.
From retrospective data [2–12] we understand that
re-RT is feasible and that toxicity, if it occurs does not
appear to be significant or clinically relevant. Despite
numerous publications on re-RT in patients with recur-
rent glioma and several active protocols, we noted that
there was no publication that specifically discussed the
approach experts would adopt when faced with a poten-
tial re-RT case especially outside of a study protocol.
Specifically, the question of our survey rested with the
treatment volume, margins, dose and fractionation and
more so than patient selection (seeing as this an evolving
topic in and of itself with several available scoring sys-
tems [14–18]. It is this information that we are fre-
quently consulted on as re-RT experts and therefore, we
felt that it was important to the recurrent glioma re-RT
field to publish an approach other providers could follow
and to provide a platform that others could contribute
to (the live survey link below) in order to advance the
field. To our knowledge this is in the only such survey
and the only paper to discuss volumes, margins, dose
and fractionation with respect to re-RT.
We obtained the opinion of radiation oncologists who
share an interest in re-RT of patients with recurrent gli-
oma using a simple survey involving 5 re-RT cases that
could represent more common scenarios encountered in
clinic as starting point for discussion and development
of consensus. The responders share some common fea-
tures including 1) all except one have treated more than
20 patients, although 3 of them have treated more than
a 100, 2) they see at least 2 patients referred for re-RT
per month and 3) treat at least 1 patient per month.
With the data presented here on 13 responders, the
numbers were insufficient to draw any conclusions with
respect to difference in approach to patient selection or
management based on the level of expertise of the
responders although it is likely that such trends may
emerge once the paper is published, readers take the
survey and more data is available. We are aware of re-
irradiation being practiced in the community as well as
in academic centers and this too will be interesting to
analyse. The volume seen in the community is likely far
smaller than what the experts in the our paper have,
which in a sense makes ours more homogenous of a
cohort. Patient selection criteria, dose and fractionation
to be employed are heterogeneous. Equally so is the
perceived impact of previously administered dose to
OAR with most responders rating it as extremely or
very important while proceeding to re-RT with doses
that are often unlikely to respect dose constraints. Des-
pite the dose to the OAR having been reached dose
limit in the first radiation course in all but one patient,
greater than 50% of responders elected to offer re-RT
in all but one case in which per responders’ comments,
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the reason for not offering re-RT was tumor size as op-
posed to dose to OAR. Perhaps this reflects a belief in
normal tissue repair with increasing time from previous
RT or a belief in lower dose per fraction decreasing the
risk of late toxicity. These two considerations could be
reflected in the minimal use of SRS (case 1 and 2).
Small volume “in field” recurrence in a young patient
with a disease free interval of 2 years (case 1) prompted
close agreement among responders all of whom perceived
this case as an opportunity to elicit local control for the
patient while considering both the risk of possible toxicity
and the potential for longevity. Most responders chose a
smaller margin and some employed SRS, although clearly
hypofractionation was still favored by most responders
irrespective of their geographical practice location. Three
responders did choose to include T2 FLAIR and/or FDG-
PET avid areas extending beyond the T1 gadolinium vol-
ume and some also pointed out that they would ultimately
decide on their dose per fraction depending on dose previ-
ously administered to OAR. Offering clinical trials as well
as considering concurrent chemotherapy with BEV and/or
Lomustine was also mentioned.
The “out of field” BEV failure case (case 2) prompted
the use of larger margins with concern for more exten-
sive occult disease presence due to previous treatment
with BEV. There was increased use of hypofractionation
and conventional fractionation as opposed to SRS. Even
when single fraction SRS was mentioned, the responders
felt that hypofractionation should be considered and dis-
cussed with the patient. Several responders commented
on this case representing an out of field recurrence,
hence the willingness and ability to treat to full dose but
also the concern that treatment of the T1 gadolinium
enhancing tumor without addressing the T2 FLAIR or
employing a larger margin, could result in marginal fail-
ure. In keeping with this view, 4 responders also chose
to include the original resection cavity despite this being
an out of field recurrence where the original resection
cavity had remained stable. This too caused responders
to favor hypofractionation or conventional fractionation
over single fraction SRS.
A large volume recurrence with maximal previous
dose to OAR (case 3), caused almost half the responders
to not offer re-RT favoring either clinical trial or best
supportive care. Responders also commented that re-RT
could only be recommended if the OAR could be spared.
Of the responders who did offer re-RT some rationalized
that the long natural history and superior KPS did justify
large volume re-RT but also stated that they would avoid
hypofractionation.
In the older patient with a disease interval of less than a
year from the original radiation (case 4) most responders
would not offer re-RT, favoring systemic treatment or
other options. The options included BEV plus CCNU,
BEV alone or possible tumor treating fields (TTF). The
responders who did offer re-RT in this case did so while
expressing the concern of this representing possible pseu-
doprogression and the need to rule this out.
The case of recurrent anaplastic astrocytoma (case 5)
was more split between resection or clinical trial and
re-RT. Some of those who would re-RT, commented that
they would consider a biopsy of the original cavity to
help decide as to whether they would include it in their
volume vs. treating the new enhancement alone. Some
expressed that this was a limited volume out of field
recurrence where optic nerve tolerance would play a role
in re-RT planning and therefore they would treat the
recurrent region only, given that the optic apparatus had
previously received maximal dose. Two responders
stated that they would treat with concurrent BEV and
another that they would treat aggressively considering
the long interval from previous RT. Some commented
on foregoing treatment of the T2 FLAIR signal area as
enveloping the chiasm and would especially consider
doing so if systemic concurrent treatment were given.
This case reflected the most heterogeneity in terms of
volume to be treated and the use of systemic treatment
as well as underlying rationale.
The question of clinical benefit as well as the concern
over toxicity are not being addressed in this paper and
remain a matter of debate in the absence of robust ran-
domized trials that carry a best supportive care arm.
Re-RT remains therefore remains controversial. We ac-
knowledge that many patients are not referred for re-RT
due to real or perceived lack of clinical benefit on the
part of the provider. Therefore, the patients who do ob-
tain re-RT reflect some level of selection bias. Cases
attempting to elucidate the perception of clinical benefit
on the part of the provider and hence the decision to
offer re-RT were deliberately included in the question-
naire (especially so Case 3 and 4). We also acknowledge
that this paper represents a reflection of the current
practice in a number of centers who do practice re-RT.
Prospective evidence is lacking.
Overriding patterns of practice/recommendations for
management:
1 Offer re-RT to patients with smaller recurrences,
especially if:
 located in a favorable location.
 ability to spare or minimize dose to OAR.
 long interval since previous RT defined as greater
than or equal to 6 months.
 well defined area of recurrence ie. no previous use of
BEV/BEV failure.
 consider SRS or hypofractionated dose/fractionation
in cases that meet size and location criteria above.
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2 Consider clinical trial, systemic treatment or best
supportive care in cases with:
 Large volume recurrence.
 Short interval since previous RT defined as less than
6 months.
 unclear clinical and radiographic progression in the
absence of tissue confirmation.
3 Consider re-RT on a case by case basis in scenarios
where:
 OAR have received maximal dose previously and
cannot be spared if further RT given.
 Surgical resection possible.
 If re-RT is proposed in cases where OAR toxicity is
a concern, most responders would favor conven-
tional fractionation over hypofractionation.
The lack of published toxicity following re-RT in the
setting of doses that exceed published dose constraints
reflect the limited life expectancy of patients treated as
well as perhaps a significant tumor related neurologic
deterioration which prevents adequate attribution of
toxicity following re-RT. The authors recommend rigor-
ous testing of visual fields, audiology, neurocognitive
function prior to and following re-RT to better examine
possible impact on toxicity as well as patient reported
outcomes for quality of life metrics.
The cumulative dose administered to OAR as a result
of re-RT and therefore the impact of those doses
remains unclear. The limited toxicity observed should be
examined further as per testing above but also should
prompt the collection of OAR doses among the RT
treatments for the purposes of designing a model of tox-
icity risk. Current guidelines [19, 20] lack the data to
make recommendations or offer risk estimation for
doses above 60 Gy or with hypofractionated regimens.
The following were not addressed in this study and re-
quire further research: the most optimal timing of re-RT,
the co-administration of systemic agents and the impact
of re-RT on brain imaging specifically the interpretation
of treatment failure versus tumor progression on MRI.
Seeing as the process underlying the decision to offer
re-RT is more complex than the patient or disease
specific factors deemed relevant in the questionnaire, we
suspect that the decision to offer re-RT is likely based
on a collection of case features as summarized in the
“Overriding patterns of practice/recommendations for
management” section. The need to understand this
better in a larger sample is part of the rationale for the
inclusion of a live link available for the duration of a year
following publication. This survey will be available as
live link (https://www.surveymonkey.com/r/G7MWVZ8)
for radiation oncologists willing to take it for one year
from publication and results thereof will be published
once available.
Conclusions
Data for the optimal administration of re-RT is lacking
but some overriding concepts emerged in this survey
governing the administration of re-RT within and out-
side of a clinical trial as evidenced by the authors. Exist-
ing prognostic scores need to be further refined to
reflect the outcome of patients with recurrent glioma
who undergo re-RT. Ultimately it appears that patient
selection is predicated on time since previous RT, previ-
ously administered dose and tumor volume, some of
which are not currently addressed in scoring systems.
Ongoing collaboration and focus on patient selection for
re-RT will continue to enable the development of scor-
ing systems that reflect patient outcome, provider clin-
ical impression and radiobiology principles.
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